He joined Jitsubo in 2016 as Director of R&D and became CEO in December 2017. Prior to Jitsubo he was responsible for quality assurance of investigational drugs at Daiichi Sankyo Co., Ltd (2007) and engaged in development of anti-cancer agents and antibacterial agents at Daiichi Pharmaceutical Company after obtaining Ph.D. from Keio University in 1987.
He was a visiting scientist to Pfof. Rick L. Danheiser at MIT (1989-90)
He joined Jitsubo in 2017 as a board member and became Executive Vice President in December 2019. Prior to Jitsubo, he held management positions in companies, Director, Universal Materials Incubator (2015), CTO, Inoac Corporation (2006), Chairman, Microhard Corporation(2004), President, JASDIC Park Co. (1997), President, KK Raychem (1886) and VP, Celanese Japan (1983). He also worked as a management consultant at McKinsey Inc, (1977) and project manager at JGC Corporation after he obtained chemical engineering degree from Waseda University (1964)
SHINSEI CORPORATE INVESTMENT LIMITED
|Vice President, Accounting Dept.
Sosei Group Corporation
|Audit & Supervisory Board Member
|TSUYOSHI DAI & PARTNERS|
|Company Name||Jitsubo CO., LTD.|
|Address||Life Science Research Center 4-1 1-1-43 Suehiro-cho, Tsurumi, Yokohama, Kanagawa-pref. 230-0045 Japan|
|Founded||April 8, 2005|
|Equity Capital||302,250,000 JPY|
Development of peptide manufacturing process, Molecular Hiving ™
Contract manufacturing of APIs and Licensing